apoQlar is the developer of a medical mixed reality platform that is revolutionizing how medicine is practiced, experienced, learned, and shared.

apoQlar medical

apoQlar

apoQlar is the developer of a medical mixed reality platform that is transforming the way medicine is practiced, experienced, learned, and shared. VSI HoloMedicine® is a medically certified software platform that leverages the Microsoft HoloLens hardware to transform medical images, clinical workflows, and medical education into an interactive 3D mixed reality environment.

Improve patient outcomes, augment the clinical experience for physicians, and educate the doctors-of-tomorrow on VSI HoloMedicine®.

HoloMedicine® is a registered trademark of apoQlar GmbH in the following countries/regions: Brazil, China, EU, India, Indonesia, Malaysia, Singapore, United Kingdom, USA.

Feature availability varies by license type and region. Please consult with us for feature implementation in your workflow, ensuring alignment of the intended use with your needs and usage.

For careers opportunities you can find all current job offerings here: https://www.apoqlar.com/careers

We were honored to kick off the DCK 2024 conference with a groundbreaking opening speech by Univ.-Prof. Dr. Christiane J. Bruns, FEBS, FACS (Hon.). Prof. Bruns emphasized the importance of new technologies, AI, Cloud, VR, and MR in the field of medicine and surgery.

A highlight of the opening session was the live holographic appearance of Prof. Dr. Bruns on stage, showcasing the huge potential of HoloMedicine®. This unique experience set the tone for an inspiring and innovative conference.

We are thrilled to announce that apoQlar has launched HoloMedicine® Spaces in collaboration with Medtronic and the The Holomedicine Association at the event. This partnership is a significant step forward in integrating cutting-edge technology into medical practice.

A special thank you to Univ.-Prof. Dr. christiane Bruns, FEBS, FACS (Hon.) and Univ.-Prof. Dr. Hans Fuchs FACS FEBS (Hon.), DGKCH & der DGAV, and Medtronic for their invaluable support and collaboration in making this event a success.

#DCK2024 #HoloMedicine #MedicalInnovation #AIinMedicine #VR #MR #VisceralSurgery #Medtronic #apoQlar #HealthcareRevolution

In the ever-evolving landscape of technology, Augmented Reality (AR), Virtual Reality (VR), and Mixed Reality (MR) are transforming the way we interact with digital content and the world around us. But what exactly sets these technologies apart? Let’s break it down!

𝐀𝐮𝐠𝐦𝐞𝐧𝐭𝐞𝐝 𝐑𝐞𝐚𝐥𝐢𝐭𝐲 (𝐀𝐑)
AR overlays digital information onto the real world. Think of it as enhancing your reality with interactive elements. A popular example is Pokémon GO, where virtual creatures appear in real-world locations through your smartphone camera. AR is perfect for applications that require users to stay connected to the physical world while adding layers of useful information or interactive content.

𝐕𝐢𝐫𝐭𝐮𝐚𝐥 𝐑𝐞𝐚𝐥𝐢𝐭𝐲 (𝐕𝐑)
VR takes you into a completely digital environment, immersing you in a world that is entirely computer-generated. Using VR headsets like Meta Quest 3, users can explore virtual spaces, play immersive games, or even conduct virtual meetings. VR is ideal for experiences that benefit from total immersion, such as virtual tours or advanced simulations.

𝐌𝐢𝐱𝐞𝐝 𝐑𝐞𝐚𝐥𝐢𝐭𝐲 (𝐌𝐑)
MR blends the physical and digital worlds, allowing real and virtual elements to interact in real-time. It goes beyond simple overlays (AR) by anchoring digital objects to the real world and enabling interaction between them. Devices like the Microsoft HoloLens 2 exemplify MR, where users can place virtual objects in their physical environment and manipulate them as if they were real. MR is particularly powerful for collaborative work, education, and of course healthcare.

All these technologies are transforming the healthcare industry by enhancing medical training, improving patient care, and facilitating advanced surgical procedures.

If you want to explore the cutting-edge capabilities of the HoloMedicine® Platform, which seamlessly integrates Mixed Reality and Virtual Reality through VSI HoloMedicine® and HoloMedicine® Spaces, we invite you to visit our website and book a demo. 

Discover how our innovative solutions can transform the way we learn and experience healthcare.

#healthcare #healthcareinnovation #VR #MR #doctors

apoQlar is excited to announce the successful close of a €10 𝐦𝐢𝐥𝐥𝐢𝐨𝐧 𝐒𝐞𝐫𝐢𝐞𝐬 𝐀 funding round, marking a significant milestone in our journey. This round saw robust participation from YZR Capital, IFB Innovationsstarter GmbH and several business angels, demonstrating strong investor confidence in our vision and market potential.
 
The new capital will accelerate our product development, expand distribution networks, and enhance regulatory and research capabilities to meet the growing global demand. This funding enables us to push the boundaries of medical technology and set new standards in patient care and medical training.
 
With the support of our investors and our dedicated team across four continents, we are poised to make significant strides in the health-tech industry. We look forward to leveraging this investment to further establish our leadership and continue advancing healthcare outcomes through innovation.
 
#startup #funding #medtech #healthcare #investment #SeriesA Dörte Bunge Markus Feuerecker

In the beginning of 2024, apoQlar was privileged to showcase our pioneering solutions at conferences across the globe, spanning from Singapore to the USA. It's been an honor to connect with countless healthcare professionals and share the transformative potential of our medical extended reality HoloMedicine® Platform. The positive feedback has been truly overwhelming and inspiring. We're eagerly looking forward to meeting many more of you in the months ahead! 
 
Join us on this journey, let's innovate healthcare together! Get in touch via info@apoQlar.com

#healthcareinnovation #doctors #healthcare #healthtech #medicine

At apoQlar, we are committed to raising awareness and providing insights on critical health issues. Today, we turn our focus to liver cancer, a condition that affects thousands of lives worldwide. Understanding liver cancer can lead to early detection and more effective treatment, ultimately saving lives.
 
Liver cancer, or hepatic cancer, begins in the cells of the liver. The most common type is hepatocellular carcinoma (HCC), which starts in the main type of liver cell (hepatocyte).
 
Several factors can increase the risk of developing liver cancer:

   • Chronic infection with hepatitis B or C virus
   • Cirrhosis (scarring of the liver)
   • Certain inherited liver diseases
   • Diabetes
   • Nonalcoholic fatty liver disease
   • Exposure to aflatoxins (poisons produced by molds that grow on crops)
   • Excessive alcohol consumption

We leverage cutting-edge technology to enhance medical imaging and treatment planning. Our HoloMedicine® Platform uses extended reality to assist surgeons in visualizing liver anatomy and tumors with unparalleled clarity ahead of surgical procedures. This innovation aims to improve patient outcomes.
  
Awareness and early detection are crucial in the fight against liver cancer. 
Together, we can make strides in combating this challenging disease!

#LiverCancer #CancerAwareness #medtech #healthcare #doctors

apoQlar is thrilled to unveil the HoloMedicine® Spaces at DCK 2024, a cutting-edge medical professional education solution that leverages the latest in XR technology to provide immersive learning experiences. 

This initiative is part of a collaborative effort with The Holomedicine Association and Medtronic, highlighting how these partnerships are propelling the future of healthcare education and technological innovation. 

Join us at the forefront of medical excellence and discover how we are collectively setting new standards in the industry. Experience the future of medicine with us at DCK 2024.

#AI #VirtualReality #healthcare #healthcareinnovation #medicine #DCK2024 #Chirurgiekongress Meta

COM:APOQLAR

apoQlar

locale

market

industry

website

crunchbase

linkedin

founding date

investor of

Metrics